title: CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
abstract: We describe a 69-year-old Japanese male with acute leukemia with a CD7+ and CD56+ immunophenotype presenting with multiple lymphadenopathy. He was treated with idarubicin and cytosine arabinoside. Although the leukemia showed partial response, the patient did not achieve complete remission. He died of sepsis due to severe neutropenia after the third course of chemotherapy. His autopsy revealed blast infiltration in the lymph nodes, liver, spleen and vertebral bone marrow. Recently, CD7+ and CD56+ myeloid/natural killer precursor acute leukemia has been associated with a poor prognosis. Our case illustrates that myeloid/natural killer cell precursor acute leukemia shows some response to intensive chemotherapy for acute myeloid leukemia, but such therapy is insufficient to effect a cure. To overcome the resistance of this disease to chemotherapy, further studies should explore other treatment strategies.
authors.affiliation: Third Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Sachiko
authors.initials: S
authors.lastname: Motohashi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Isozumi
authors.forename: Satoru
authors.initials: S
authors.lastname: Komatsumoto
authors.forename: Masaharu
authors.initials: M
authors.lastname: Nara
mesh_terms: D000208:Acute Disease; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D019011:Antigens, CD7 / Q000032:analysis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019002:CD56 Antigen / Q000032:analysis*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003630:Daunorubicin / Q000008:administration & dosage; D003937:Diagnosis, Differential; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007694:Killer Cells, Natural / Q000737:chemistry / Q000473:pathology*; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D017254:Leukemic Infiltration; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D022423:Myeloid Cells / Q000737:chemistry / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis; D023981:Sarcoma, Myeloid / Q000175:diagnosis; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D015703:Antigens, CD; D019011:Antigens, CD7; D015214:Antigens, Differentiation, Myelomonocytic; D000951:Antigens, Neoplasm; C571163:CD33 protein, human; D019002:CD56 Antigen; D063268:Sialic Acid Binding Ig-like Lectin 3; D003561:Cytarabine; D005047:Etoposide; C015019:enocitabine; D008942:Mitoxantrone; D015122:Mercaptopurine; D015255:Idarubicin; D003630:Daunorubicin